Developer docs
API playgroundTry for free, no card

Search company profiles

Kymanox

Full company profile

uuid0008wud

Namestring
Kymanox
Legal namestring
Kymanox Corporation
Websiteurl
kymanox.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Kymanox Corporation is a life sciences professional services firm founded in 2004 and headquartered in Morrisville, North Carolina. The company provides integrated engineering, scientific, regulatory, compliance, and project management consulting services to pharmaceutical, biotechnology, medical device, and combination product developers. Kymanox organizes its work around five core focus areas — Combination Products, Biologics & Advanced Therapies, Design/Development/Testing, Facilities & Manufacturing Services, and Quality & Compliance — with deeper sub-services spanning CMC, human factors engineering, sterilization engineering, validation (CQV), analytical sciences, drug delivery device design, and regulatory affairs. The company claims 4,000+ projects completed in the past year and a 100% success rate in client regulatory inspections (PAI, PLI).

The firm operates without a proprietary technology platform and monetizes through project-based engagements and retainer arrangements with enterprise clients. Go-to-market is direct enterprise sales supported by a thought-leadership engine: a website with regular blog content, a 10,000+-subscriber newsletter, the Life Science Solutions podcast, an extensive case-study library, and active participation in industry conferences (PDA/FDA Joint Regulatory Conference, DDF Summit, PDA Universe). Delivery is supported by offices in Morrisville NC, King of Prussia PA, Bern, and Munich, and an emerging Hyper-Virtual Model for remote engagements.

Since a 2021 growth recapitalization by WestView Capital Partners, Kymanox has executed four acquisitions — Neuma (August 2021, drug delivery services), Anteris Medical GmbH and Anteris Helvetia AG (February 2023, European expansion), Agilis Consulting Group (March 2023, regulatory strategy and human factors), and an earlier 2014 Freedom Labs deal — building a multi-brand life sciences services platform across the US and EU. The company is privately held and operates as a portfolio company under WestView's sponsorship with debt facilities arranged by Abacus Finance Group.

Short descriptiontext

Kymanox is a life sciences professional services firm providing integrated engineering, regulatory, quality, and project management consulting to pharmaceutical, biotechnology, medical device, and combination product companies across the US and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences consulting, regulatory affairs services, combination product development, biologics manufacturing support, medical device engineering
Product category
Life Sciences Consulting Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Professional Services
TypeProfessional Services
Description

Kymanox generates revenue through consulting and professional services engagements, providing specialized expertise in regulatory strategy, quality and compliance, design and development, facilities and manufacturing services, and project management for life sciences clients. Services are delivered through project-based engagements and retainer arrangements with pharmaceutical, biotech, medical device, and combination product companies.

kymanox.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Kymanox Executive Advisors
Description

Executive advisory services offered by Kymanox to support life science industry clients

kymanox.com
Core offering1 text field

Kymanox is a life sciences professional services firm that provides integrated engineering, scientific, regulatory, quality, and project management support to biotechnology, pharmaceutical, medical device, and combination product companies. Services span the product lifecycle from development through commercialization, delivered via project-based consulting engagements and retainer arrangements, with sub-offerings covering combination products, biologics & advanced therapies, design/development/testing, facilities & manufacturing services, and quality & compliance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 4,000+ projects completed in the last year
+2 more records
Product overview1 text field

Kymanox is a life sciences professional services company offering integrated consulting services across five core areas: Combination Products, Biologics & Advanced Therapies, Design/Development & Testing, Facilities & Manufacturing Services, and Quality & Compliance. The company operates as a unified platform with specialized sub-services including Clinical Affairs, CMC, Human Factors Engineering, Sterilization Engineering, Validation (CQV), Quality Management Systems, Project Management, Analytical Sciences, Drug Delivery Device Design, and Regulatory Affairs. Additional offerings include the Kymanox Executive Advisors (KEA) sub-brand for strategic consulting and a Hyper-Virtual Model for remote service delivery. The company also produces the Life Science Solutions podcast as thought leadership content. Kymanox supports biotechnology, pharmaceutical, medical device, and combination product companies throughout the product lifecycle from clinic to commercial.

Product and service8 records
1Combination Products Services
CategoryCombination Product Consulting
Description

Integrated drug-device consulting offering covering CMC/Pharma Science, Product & Device Development, Manufacturing Science & Technology, Clinical Affairs, Human Factors Engineering, Regulatory Affairs, Strategic Support, and Project Management for combination product developers.

2Biologics & Advanced Therapies Services
CategoryBiologics Consulting
Description

Expert-driven consulting solutions for biotechnology companies covering CMC/Pharma Science, Process Engineering, Regulatory Affairs & Quality Assurance, Supply Chain & Logistics, and Digital Solutions, focused on monoclonal antibodies and advanced therapies.

3Design, Development, and Testing Services
CategoryEngineering and Product Development Consulting
Description

Human-centered design, robust testing, and engineering consulting covering Design & Innovation, Product & Device Development, Test Engineering, Human Factors Engineering, Sterilization Engineering, and Quality Assurance for medical devices and combination products.

4Facilities & Manufacturing Services
CategoryManufacturing and Facilities Consulting
Description

Operational readiness and scalable consulting solutions spanning Facility & Utility Engineering, Automation, Validation (CQV), Computer System Validation, Quality Assurance, Analytical Sciences, Process Engineering & Technology Transfer, and Project Management for life sciences manufacturers.

5Quality & Compliance Services
CategoryQuality and Compliance Consulting
Description

Consulting services ensuring safety, efficacy, and compliance, including Quality Leadership, Quality & Event Management, Audits & Inspection Readiness, Quality Engineering, and Regulatory Affairs for life sciences clients.

6Ancillary Support Services
CategoryAdvisory and Project Management Consulting
Description

Supplementary consulting offerings including Regulatory Affairs, Executive Strategy, and Project Management, delivered through alternative business models such as the Emerging Enterprise and Hyper Virtual Model.

7Kymanox Executive Advisors (KEA)
CategoryExecutive Advisory Services
Description

Executive strategy consulting sub-brand offering senior advisory support to life science organizations.

8Hyper-Virtual Model
CategoryConsulting Delivery Model
Description

Virtual consulting delivery model enabling remote life science consulting services for clients requiring distributed engagement.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kymanox acquired Agilis Consulting Group in March 2023 to expand its service capabilities in regulatory strategy and human factors for life sciences clients. The acquisition enhances the companies' ability to support bringing new medicines, biologics, and medical devices to market.

2Anteris Medical GmbH and Anteris Helvetia AG
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kymanox acquired Anteris Medical GmbH (Germany) and Anteris Helvetia AG (Switzerland) in February 2023 to expand capabilities and geographic reach within the life science industry. The acquisition enhances services related to development and commercialization of medical devices, combination products, and biologics.

finance.yahoo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kymanox acquired Neuma, a drug delivery services provider based in Pennsylvania in August 2021, to expand its capabilities in medical device technologies and support early-stage programs. The deal followed Kymanox's growth capital investment from WestView Capital Partners.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kymanox

Life Sciences Consulting Serviceskymanox.com

Kymanox is a life sciences professional services firm providing integrated engineering, regulatory, quality, and project management consulting to pharmaceutical, biotechnology, medical device, and combination product companies across the US and Europe.

What Kymanox does

Kymanox Corporation is a life sciences professional services firm founded in 2004 and headquartered in Morrisville, North Carolina. The company provides integrated engineering, scientific, regulatory, compliance, and project management consulting services to pharmaceutical, biotechnology, medical device, and combination product developers. Kymanox organizes its work around five core focus areas — Combination Products, Biologics & Advanced Therapies, Design/Development/Testing, Facilities & Manufacturing Services, and Quality & Compliance — with deeper sub-services spanning CMC, human factors engineering, sterilization engineering, validation (CQV), analytical sciences, drug delivery device design, and regulatory affairs. The company claims 4,000+ projects completed in the past year and a 100% success rate in client regulatory inspections (PAI, PLI).

The firm operates without a proprietary technology platform and monetizes through project-based engagements and retainer arrangements with enterprise clients. Go-to-market is direct enterprise sales supported by a thought-leadership engine: a website with regular blog content, a 10,000+-subscriber newsletter, the Life Science Solutions podcast, an extensive case-study library, and active participation in industry conferences (PDA/FDA Joint Regulatory Conference, DDF Summit, PDA Universe). Delivery is supported by offices in Morrisville NC, King of Prussia PA, Bern, and Munich, and an emerging Hyper-Virtual Model for remote engagements.

Since a 2021 growth recapitalization by WestView Capital Partners, Kymanox has executed four acquisitions — Neuma (August 2021, drug delivery services), Anteris Medical GmbH and Anteris Helvetia AG (February 2023, European expansion), Agilis Consulting Group (March 2023, regulatory strategy and human factors), and an earlier 2014 Freedom Labs deal — building a multi-brand life sciences services platform across the US and EU. The company is privately held and operates as a portfolio company under WestView's sponsorship with debt facilities arranged by Abacus Finance Group.

Kymanox firmographics

Firmographics
Name
Kymanox
Legal name
Kymanox Corporation
Website
https://kymanox.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
Kymanox is a life sciences professional services firm providing integrated engineering, regulatory, quality, and project management consulting to pharmaceutical, biotechnology, medical device, and combination product companies across the US and Europe.
Ownership category
akta.pro rank

Where Kymanox is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Kymanox business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Professional Services: Kymanox generates revenue through consulting and professional services engagements, providing specialized expertise in regulatory strategy, quality and compliance, design and development, facilities and manufacturing services, and project management for life sciences clients. Services are delivered through project-based engagements and retainer arrangements with pharmaceutical, biotech, medical device, and combination product companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Kymanox product offering

Product offering

Core offering

Kymanox is a life sciences professional services firm that provides integrated engineering, scientific, regulatory, quality, and project management support to biotechnology, pharmaceutical, medical device, and combination product companies. Services span the product lifecycle from development through commercialization, delivered via project-based consulting engagements and retainer arrangements, with sub-offerings covering combination products, biologics & advanced therapies, design/development/testing, facilities & manufacturing services, and quality & compliance.

Product overview

Kymanox is a life sciences professional services company offering integrated consulting services across five core areas: Combination Products, Biologics & Advanced Therapies, Design/Development & Testing, Facilities & Manufacturing Services, and Quality & Compliance. The company operates as a unified platform with specialized sub-services including Clinical Affairs, CMC, Human Factors Engineering, Sterilization Engineering, Validation (CQV), Quality Management Systems, Project Management, Analytical Sciences, Drug Delivery Device Design, and Regulatory Affairs. Additional offerings include the Kymanox Executive Advisors (KEA) sub-brand for strategic consulting and a Hyper-Virtual Model for remote service delivery. The company also produces the Life Science Solutions podcast as thought leadership content. Kymanox supports biotechnology, pharmaceutical, medical device, and combination product companies throughout the product lifecycle from clinic to commercial.

Differentiator

Problem solved

Functional benefit

Brands

  • Kymanox Executive Advisors: Executive advisory services offered by Kymanox to support life science industry clients

Products and services

  • Combination Products Services Integrated drug-device consulting offering covering CMC/Pharma Science, Product & Device Development, Manufacturing Science & Technology, Clinical Affairs, Human Factors Engineering, Regulatory Affairs, Strategic Support, and Project Management for combination product developers.
  • Biologics & Advanced Therapies Services Expert-driven consulting solutions for biotechnology companies covering CMC/Pharma Science, Process Engineering, Regulatory Affairs & Quality Assurance, Supply Chain & Logistics, and Digital Solutions, focused on monoclonal antibodies and advanced therapies.
  • Design, Development, and Testing Services Human-centered design, robust testing, and engineering consulting covering Design & Innovation, Product & Device Development, Test Engineering, Human Factors Engineering, Sterilization Engineering, and Quality Assurance for medical devices and combination products.
  • Facilities & Manufacturing Services Operational readiness and scalable consulting solutions spanning Facility & Utility Engineering, Automation, Validation (CQV), Computer System Validation, Quality Assurance, Analytical Sciences, Process Engineering & Technology Transfer, and Project Management for life sciences manufacturers.
  • Quality & Compliance Services Consulting services ensuring safety, efficacy, and compliance, including Quality Leadership, Quality & Event Management, Audits & Inspection Readiness, Quality Engineering, and Regulatory Affairs for life sciences clients.
  • Ancillary Support Services Supplementary consulting offerings including Regulatory Affairs, Executive Strategy, and Project Management, delivered through alternative business models such as the Emerging Enterprise and Hyper Virtual Model.
  • Kymanox Executive Advisors (KEA) Executive strategy consulting sub-brand offering senior advisory support to life science organizations.
  • Hyper-Virtual Model Virtual consulting delivery model enabling remote life science consulting services for clients requiring distributed engagement.

Quantifiable outcome

  • 4,000+ projects completed in the last year
  • +2 more outcomes

Companies that use Kymanox

Customer profile

Segments4 records

Ideal customer profiles1 record

Kymanox technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kymanox partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Agilis Consulting GroupcoreStrategic or Co-development PartnerKymanox acquired Agilis Consulting Group in March 2023 to expand its service capabilities in regulatory strategy and human factors for life sciences clients. The acquisition enhances the companies' ability to support bringing new medicines, biologics, and medical devices to market.
  • Anteris Medical GmbH and Anteris Helvetia AGcoreStrategic or Co-development PartnerKymanox acquired Anteris Medical GmbH (Germany) and Anteris Helvetia AG (Switzerland) in February 2023 to expand capabilities and geographic reach within the life science industry. The acquisition enhances services related to development and commercialization of medical devices, combination products, and biologics.
  • NeumacoreStrategic or Co-development PartnerKymanox acquired Neuma, a drug delivery services provider based in Pennsylvania in August 2021, to expand its capabilities in medical device technologies and support early-stage programs. The deal followed Kymanox's growth capital investment from WestView Capital Partners.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Kymanox competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Kymanox social profiles

Digital presence

Kymanox financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kymanox leadership team

Management profile

Number of profiles

Profiles5 records

Kymanox subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Kymanox funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kymanox M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kymanox

What does Kymanox do?

Kymanox is a life sciences professional services firm that provides integrated engineering, scientific, regulatory, quality, and project management support to biotechnology, pharmaceutical, medical device, and combination product companies. Services span the product lifecycle from development through commercialization, delivered via project-based consulting engagements and retainer arrangements, with sub-offerings covering combination products, biologics & advanced therapies, design/development/testing, facilities & manufacturing services, and quality & compliance.

Is Kymanox a public or private company?

Kymanox is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kymanox founded?

Kymanox was founded in 2004. It employs 101 to 250 people.

Where is Kymanox based?

Kymanox is headquartered in Morrisville, United States, in the North America region.

How does Kymanox make money?

One revenue line is on record: professional Services.

Does Kymanox have an API?

No public API is recorded for Kymanox.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireKymanox Launches AI-Enabled Quality and Regulatory Capabilities for Life Sciences OrganizationsKymanox launched AI-enabled quality and regulatory services for life sciences, using its KAI Engine with expert verification. The initial offerings cover QMS development, batch release review, and human factors study optimization, with data security and privacy measures. The company plans to expand these services in late 2026 and 2027.GlobeNewswireKymanox Launches AI-Enabled Quality and Regulatory Capabilities for Life Sciences OrganizationsKymanox, a global life science professional services and consulting firm, announced the launch of its proprietary KAI (Kymanox Artificial Intelligence) Engine for pharmaceutical, biotechnology, medical device, and combination product companies. The AI-enabled solution applies task-specific AI workflows to three quality and regulatory service areas—QMS Development, Batch Release Report Review, and Human Factors Study Optimization—with qualified Kymanox experts verifying every output. The Human Factors offering was developed in partnership with Sanai, and the capabilities are available now with expansion planned throughout 2026 and 2027.Business InsiderKymanox Launches AI-Enabled Quality and Regulatory Capabilities for Life Sciences OrganizationsKymanox launched proprietary AI-enabled solutions for quality and regulatory services in the life sciences sector, powered by its KAI Engine. The offering includes capabilities for QMS development, batch release report review, and human factors study optimization, with the latter developed in partnership with Sanai. Every AI-assisted output is verified by qualified Kymanox subject matter experts to ensure compliance with regulated industry standards.BiobuzzThree Philly-Area Startups Accelerating Breakthroughs and Milestones with Lean Commercialization ApproachThree startups based in Eastern Pennsylvania, BioLattice Ophthalmics, Balanced Pharma, and SterilMetric Innovations, showcased their advancements in medical device and biotech during the 2nd Annual Kymanox Showcase. These companies are developing innovative solutions in vision restoration, dental anesthesia, and sterilization technology while maintaining lean operations and attracting significant capital.BiobuzzFuture of Healthcare: AI, Blockchain, and Trust RedefinedStephen M. Perry, CEO of Kymanox, outlined a future where AI, blockchain, and biotech converge to redefine trust in healthcare. He predicted by 2030 that companies will lease therapy benefits and that startups under nine employees will drive 40% of Kymanox's business. Perry urged leaders to balance optimism with realism as the industry resets.BiobuzzEmbracing AI: How North Carolina Leads Biotech's FutureStephen M. Perry, CEO of Kymanox, delivered closing remarks at North Carolina Life Sciences Week, highlighting AI's transformative role in biotech. He noted major companies like Amgen and Genentech are expanding in North Carolina, and urged the ecosystem to move forward together.GlobeNewswireSilo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain ManagementSilo Pharma announced a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 ketamine implant targeting chronic pain and fibromyalgia. Kymanox will conduct proof-of-concept design and prototype testing to determine optimal insertion depth. If approved, SP-26 could become the first at-home injectable ketamine-based therapeutic.PR Newswire5 Key Takeaways for Reducing Risk in Pharma MarketingGroup 31 CEO Crystal Weber appeared on the podcast The Factor by Kymanox to discuss risk reduction strategies in pharma marketing for biotech companies. The interview yielded five key takeaways covering topics such as beginning marketing efforts pre-label, building brand recognition early, maintaining factual accuracy, leveraging regulatory expertise, and selecting appropriate agency partners. This content was published by Group 31 Communications, a healthcare marketing agency founded in 2010 that supports emerging and midsized pharmaceutical companies.PR NewswireUne étude montrant la voie vers une réduction significative des émissions de gaz à effet de serre dans la chaîne d'approvisionnement des dispositifs médicaux sera publiée le 30 juillet 2024, 8:45 ETA peer-reviewed study published on July 30, 2024, by researchers Robert Litan and Matthew Eckelman, with support from Kymanox engineers, found that ApiJect Systems' blow-fill-seal (BFS) prefilled injectors produce significantly lower greenhouse gas emissions than traditional glass syringes, generating only 38g CO2 equivalent per dose compared to 125% higher emissions for single-dose glass vials and 100% higher for Luer-type prefilled syringes.PR NewswireStudie zeigt Möglichkeiten zur erheblichen Reduzierung von Treibhausgasemissionen in der Lieferkette für medizinische Geräte - Veröffentlichung am 30. Juli 2024, 8:45 AM ETA peer-reviewed study published on July 30, 2024, found that the Prefilled ApiJect Injector developed by ApiJect Systems produces just 38g CO2-eq per dose, representing approximately 125% lower greenhouse gas emissions than single-dose glass vials and more than 100 times less water usage for manufacturing, cleaning, and sterilization. The one-year study was authored by Dr. Robert Litan and Dr. Matthew Eckelman of Yale School of Public Health, with engineering and scientific support from Kymanox, a life sciences-only services firm.